First-line therapy in EGFR-mutant NSCLC

Dr. Biagio Ricciuti of Dana-Farber Cancer Institute (USA) talks with Dr. Marcelo Corassa of Beneficência Portuguesa de São Paulo (Brazil) about the treatment of EGFR-mutant non-small cell lung cancer: the results of FLAURA, MARIPOSA and FLAURA2, and future directions.

More episodes

All episodes

Prostate cancer statistics 2025Dr. Gil Morgan and Mr. Tyler KratzerSeason 2, Episode 2, September 25, 2025
The BULLSEYE trial and PSMA radioligandsDr. Danny Mena and Dr. Barbara MelãoSeason 2, Episode 1, September 7, 2025
Upper tract urothelial carcinomaDr. Philippe Spiess and Dr. Barbara MelãoSeason 1, Episode 6, May 20, 2025
Annual Report to the Nation on the Status of CancerDr. Gil Morgan and Dr. Ahmedin JemalSeason 1, Episode 5, April 28, 2025
Supportive care and telemedicineDr. Joseph McCollom and Dr. Cristiane BergerotSeason 1, Episode 3, March 26, 2025
Adjuvant CDK4/6 inhibitors in breast cancerDr. Maryam Lustberg and Dr. Elisa AgostinettoSeason 1, Episode 2, March 14, 2025

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details

First-line therapy in EGFR-mutant NSCLC

More episodes

The week in oncology, in your inbox